Gallium Ga 68 dotatate
A radiolabelled peptide that maps neuroendocrine tumours
Gallium Ga 68 dotatate is the somatostatin analogue octreotate, linked to a DOTA chelator and loaded with radioactive gallium-68. Injected before a PET scan, it binds the somatostatin receptors on most neuroendocrine tumours and shows where they are. FDA approved the Netspot kit in 2016.
What is it?
Most well-differentiated neuroendocrine tumours carry many somatostatin receptors. Octreotate, a stable analogue of the hormone somatostatin, binds them tightly, and attaching a radioactive label turns it into a way of seeing the tumours. Gallium-68 is a positron emitter with a 68-minute half-life, so the scan is done soon after injection.
Gallium-68 PET largely replaced the older indium-111 pentetreotide scans. A meta-analysis of ten studies found pooled per-patient sensitivity of 96% and specificity of 100% for gallium-68 dotatate,. The same peptide carrying lutetium-177 is used to treat these tumours, which is why the scan also helps select patients for that therapy. A 2016 systematic review also found it more sensitive than indium-111 octreotide in same-patient comparisons, with rare reports of harm. In one survey of referring physicians, the scan led to intended management changes in 60% of 88 patients.
The label notes radiation risk, hypersensitivity reactions and a risk of image misinterpretation, because uptake can occur in other conditions. It is approved for adults and children.
At a Glance
Every value in this table is printed from the Grey Peptides dataset, the same record the compound explorer and comparison tool read, so the three can never disagree.
Half-Life: How Much Remains
The dataset records a half-life of gallium-68 physical half-life 68 minutes for Gallium Ga 68 dotatate. After each half-life, half of what was in the circulation is gone, so about 3% remains after five. Real clearance varies with the person, the dose, the route and kidney or liver function; this is arithmetic on a published figure, not a dosing tool.
Published Research
Studies of gallium-68 dotatate, from their PubMed abstracts.
Diagnostic accuracy meta-analysis
Across ten studies of 416 patients, pooled per-patient sensitivity was 96% and specificity 100% for gallium-68 DOTATATE PET (93% and 85% for DOTATOC), with an area under the curve of 0.98.
Against indium-111 octreotide and conventional imaging
A systematic review of 42 eligible studies found gallium-68 DOTATATE more sensitive than indium-111 octreotide in same-patient comparisons, with estimated sensitivity 90.9% and specificity 90.6% against conventional imaging; possible harms were rare (6 of 974) and no major toxicity was reported.
Effect on management: referring physicians' view
In 88 patients, referring physicians reported intended management changes after gallium-68 DOTATATE PET/CT in 60%; 23% scheduled for chemotherapy were switched to treatments without chemotherapy.
Ectopic ACTH syndrome
In a prospective study of tumours causing ectopic ACTH syndrome, gallium-68 DOTATATE PET had a sensitivity of 79%, overlapping 18F-DOPA PET (88%) and far above octreotide scanning (31%).
Side Effects & Contraindications
Reported Side Effects
From the studies above.
Contraindications & Cautions
Warnings from the Netspot label (DailyMed, effective July 6, 2026).
Legal Status
Gallium Ga 68 dotatate is an approved prescription diagnostic in the US.
Frequently Asked Questions
?What is a gallium-68 dotatate scan?
A PET scan after an injection of a radiolabelled somatostatin analogue that binds the receptors on most neuroendocrine tumours, showing where they are.
?How accurate is it?
A meta-analysis found pooled per-patient sensitivity of 96% and specificity of 100%, and a 2016 systematic review found it more sensitive than indium-111 octreotide in same-patient comparisons.
?How is it related to Lutathera?
Lutathera uses the same octreotate peptide carrying lutetium-177 to treat neuroendocrine tumours; the gallium scan shows whether the tumours have enough receptors for it.
References
- [fda] US FDA, Drugs@FDA (openFDA): NETSPOT, NDA 208547 (June 1, 2016). Read October 3, 2026.
- [fda-pi] FDA. Netspot (kit for gallium Ga 68 dotatate) US prescribing information (DailyMed set b2b3be70-17d8-4093-896c-f1c54a2cf242, effective July 6, 2026). Read October 3, 2026.
- [pubmed] Yang J, et al. "Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis." Acta Radiol, 2014;55(4):389-98. PMID: 23928010.
- [pubmed] Deppen SA, et al. "68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis." J Nucl Med, 2016;57(6):872-8. PMID: 26769864.
- [pubmed] Herrmann K, et al. "Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: the referring physician's perspective." J Nucl Med, 2015;56(1):70-5. PMID: 25500825.
- [pubmed] Elenius H, et al. "Prospective Evaluation of 68Ga-DOTATATE and 18F-DOPA PET Scans in Detecting Tumors Causing Ectopic ACTH Syndrome." J Clin Endocrinol Metab, 2025;110(11):e3794-e3802. PMID: 40036831.
Sources & Citations
Studies were read from their PubMed records; regulatory sources are listed below, read October 3, 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Consult a licensed healthcare provider before making health decisions.